The setup for Sanofi is compared to AbbVie Inc. in 2019, which also had a low valuation and high yield due to patent cliff fears, implying a potentially similar positive outcome.
Source Post
This High-Yield Pharma Stock Looks Like a Bargain Right Now
Dividends And IncomeApr 1, 2026
The creator highlights Sanofi SA (SNY) as an undervalued dividend growth stock. The company boasts a high yield, strong dividend growth history, and significant potential from its drug Dupixent. Despite patent cliff concerns, the stock appears cheap based on valuation metrics and analyst targets, suggesting a potential 28% undervaluation.
Linked Mentions
Tickers discussed in this post
Sanofi SA (SNY) is presented as a bargain with a high yield, double-digit dividend growth, and potential 28% undervaluation, making it attractive for long-term dividend growth investors.
Linked Signals
Tracked calls opened from this post
SNY
buy opened Apr 1, 2026
-11.17%